A mikofenolát-nátrium-terápia hatása a vesetranszplantáltak életmino{double acute}ségére

G. Lazar, P. Szenohradszky, Edit Szederkényi, Ágnes Surmann, Éva Toronyi, Szilárd Török, Katalin Földes, Károly Kalmár-Nagy, Péter Szakály

Research output: Article

Abstract

Enteric-coated mycophenolate sodium (EC-MPS; Myfortic®, Novartis Pharma AG, Basel, Switzerland) is an enteric-coated formulation delivering MPA. Enteric-coated MPS has been developed with the aim of improving the upper GI tolerability of MPA while providing a therapeutical equivalence. The primary objective of the study was to measure the quality of life of kidney transplant patients, with special attention to gastrointestinal symptoms during mycophenolate sodium therapy. The secondary objective was to measure the mean daily mycophenolate sodium dose during routine therapy. These two parameters can significantly influence long-term graft survival of the patients. The study was a multicentric, non-interventional, 12 weeks, single arm, cohort, observational study, in which 251 adult, kidney transplant patients were enrolled in 4 study centers. As part of the study, the patient completed a questionnaire to assess the gastrointestinal status: the Gastrointestinal Symp - tom Rating Scale (GSRS). The patient's average age was 51.03 years by the time of the inclusion. 61% of the patients were male and 39% female. Kidney transplant was performed averagely 6.3 years (SD: 4.3 years) prior to the screening visit. At the first visit the average intensity of gastrointestinal side effects was 0.87, at the final visit was 0.28. The change of the average number of gastrointestinal side effects between the first and last visit was examined by Wilcoxon test, and it was significant (p

Original languageHungarian
Pages (from-to)257-264
Number of pages8
JournalLege Artis Medicinae
Volume25
Issue number6-7
Publication statusPublished - 2015

Fingerprint

Mycophenolic Acid
Quality of Life
Transplants
Kidney
Therapeutics
Graft Survival
Switzerland
Observational Studies
Arm
Cohort Studies

Keywords

  • Gastrointestinal side effect
  • Immun suppression
  • Life quality
  • Natrium-mycofenolate
  • Renal transplantation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lazar, G., Szenohradszky, P., Szederkényi, E., Surmann, Á., Toronyi, É., Török, S., ... Szakály, P. (2015). A mikofenolát-nátrium-terápia hatása a vesetranszplantáltak életmino{double acute}ségére. Lege Artis Medicinae, 25(6-7), 257-264.

A mikofenolát-nátrium-terápia hatása a vesetranszplantáltak életmino{double acute}ségére. / Lazar, G.; Szenohradszky, P.; Szederkényi, Edit; Surmann, Ágnes; Toronyi, Éva; Török, Szilárd; Földes, Katalin; Kalmár-Nagy, Károly; Szakály, Péter.

In: Lege Artis Medicinae, Vol. 25, No. 6-7, 2015, p. 257-264.

Research output: Article

Lazar, G, Szenohradszky, P, Szederkényi, E, Surmann, Á, Toronyi, É, Török, S, Földes, K, Kalmár-Nagy, K & Szakály, P 2015, 'A mikofenolát-nátrium-terápia hatása a vesetranszplantáltak életmino{double acute}ségére', Lege Artis Medicinae, vol. 25, no. 6-7, pp. 257-264.
Lazar, G. ; Szenohradszky, P. ; Szederkényi, Edit ; Surmann, Ágnes ; Toronyi, Éva ; Török, Szilárd ; Földes, Katalin ; Kalmár-Nagy, Károly ; Szakály, Péter. / A mikofenolát-nátrium-terápia hatása a vesetranszplantáltak életmino{double acute}ségére. In: Lege Artis Medicinae. 2015 ; Vol. 25, No. 6-7. pp. 257-264.
@article{fa57222a7bc64365bc70aef8fd0405a0,
title = "A mikofenol{\'a}t-n{\'a}trium-ter{\'a}pia hat{\'a}sa a vesetranszplant{\'a}ltak {\'e}letmino{double acute}s{\'e}g{\'e}re",
abstract = "Enteric-coated mycophenolate sodium (EC-MPS; Myfortic{\circledR}, Novartis Pharma AG, Basel, Switzerland) is an enteric-coated formulation delivering MPA. Enteric-coated MPS has been developed with the aim of improving the upper GI tolerability of MPA while providing a therapeutical equivalence. The primary objective of the study was to measure the quality of life of kidney transplant patients, with special attention to gastrointestinal symptoms during mycophenolate sodium therapy. The secondary objective was to measure the mean daily mycophenolate sodium dose during routine therapy. These two parameters can significantly influence long-term graft survival of the patients. The study was a multicentric, non-interventional, 12 weeks, single arm, cohort, observational study, in which 251 adult, kidney transplant patients were enrolled in 4 study centers. As part of the study, the patient completed a questionnaire to assess the gastrointestinal status: the Gastrointestinal Symp - tom Rating Scale (GSRS). The patient's average age was 51.03 years by the time of the inclusion. 61{\%} of the patients were male and 39{\%} female. Kidney transplant was performed averagely 6.3 years (SD: 4.3 years) prior to the screening visit. At the first visit the average intensity of gastrointestinal side effects was 0.87, at the final visit was 0.28. The change of the average number of gastrointestinal side effects between the first and last visit was examined by Wilcoxon test, and it was significant (p",
keywords = "Gastrointestinal side effect, Immun suppression, Life quality, Natrium-mycofenolate, Renal transplantation",
author = "G. Lazar and P. Szenohradszky and Edit Szederk{\'e}nyi and {\'A}gnes Surmann and {\'E}va Toronyi and Szil{\'a}rd T{\"o}r{\"o}k and Katalin F{\"o}ldes and K{\'a}roly Kalm{\'a}r-Nagy and P{\'e}ter Szak{\'a}ly",
year = "2015",
language = "Hungarian",
volume = "25",
pages = "257--264",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "6-7",

}

TY - JOUR

T1 - A mikofenolát-nátrium-terápia hatása a vesetranszplantáltak életmino{double acute}ségére

AU - Lazar, G.

AU - Szenohradszky, P.

AU - Szederkényi, Edit

AU - Surmann, Ágnes

AU - Toronyi, Éva

AU - Török, Szilárd

AU - Földes, Katalin

AU - Kalmár-Nagy, Károly

AU - Szakály, Péter

PY - 2015

Y1 - 2015

N2 - Enteric-coated mycophenolate sodium (EC-MPS; Myfortic®, Novartis Pharma AG, Basel, Switzerland) is an enteric-coated formulation delivering MPA. Enteric-coated MPS has been developed with the aim of improving the upper GI tolerability of MPA while providing a therapeutical equivalence. The primary objective of the study was to measure the quality of life of kidney transplant patients, with special attention to gastrointestinal symptoms during mycophenolate sodium therapy. The secondary objective was to measure the mean daily mycophenolate sodium dose during routine therapy. These two parameters can significantly influence long-term graft survival of the patients. The study was a multicentric, non-interventional, 12 weeks, single arm, cohort, observational study, in which 251 adult, kidney transplant patients were enrolled in 4 study centers. As part of the study, the patient completed a questionnaire to assess the gastrointestinal status: the Gastrointestinal Symp - tom Rating Scale (GSRS). The patient's average age was 51.03 years by the time of the inclusion. 61% of the patients were male and 39% female. Kidney transplant was performed averagely 6.3 years (SD: 4.3 years) prior to the screening visit. At the first visit the average intensity of gastrointestinal side effects was 0.87, at the final visit was 0.28. The change of the average number of gastrointestinal side effects between the first and last visit was examined by Wilcoxon test, and it was significant (p

AB - Enteric-coated mycophenolate sodium (EC-MPS; Myfortic®, Novartis Pharma AG, Basel, Switzerland) is an enteric-coated formulation delivering MPA. Enteric-coated MPS has been developed with the aim of improving the upper GI tolerability of MPA while providing a therapeutical equivalence. The primary objective of the study was to measure the quality of life of kidney transplant patients, with special attention to gastrointestinal symptoms during mycophenolate sodium therapy. The secondary objective was to measure the mean daily mycophenolate sodium dose during routine therapy. These two parameters can significantly influence long-term graft survival of the patients. The study was a multicentric, non-interventional, 12 weeks, single arm, cohort, observational study, in which 251 adult, kidney transplant patients were enrolled in 4 study centers. As part of the study, the patient completed a questionnaire to assess the gastrointestinal status: the Gastrointestinal Symp - tom Rating Scale (GSRS). The patient's average age was 51.03 years by the time of the inclusion. 61% of the patients were male and 39% female. Kidney transplant was performed averagely 6.3 years (SD: 4.3 years) prior to the screening visit. At the first visit the average intensity of gastrointestinal side effects was 0.87, at the final visit was 0.28. The change of the average number of gastrointestinal side effects between the first and last visit was examined by Wilcoxon test, and it was significant (p

KW - Gastrointestinal side effect

KW - Immun suppression

KW - Life quality

KW - Natrium-mycofenolate

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=84939792826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939792826&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84939792826

VL - 25

SP - 257

EP - 264

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 6-7

ER -